Dopamine type 2 and type 3 receptors (D 2 R/D 3 R) appear critical to addictive disorders. Cocaine-use disorder (CUD) is associated with lower D 2 R availability and greater D 3 R availability in regions primarily expressing D 2 R or D 3 R concentrations, respectively. However, these CUD-related alterations in D 2 R and D 3 R have not been concurrently detected using available dopaminergic radioligands. Furthermore, receptor availability in regions of mixed D 2 R/D 3 R concentration in CUD remains unclear. The current study aimed to extend investigations of CUD-related alterations in D 2 R and D 3 R availability using regional and source-based analyses of [ 11 C]-(+)-PHNO positron emission tomography (PET) of 26 individuals with CUD and 26 matched healthy comparison (HC) participants. Regional analysis detected greater binding potential (BP ND ) in CUD in the midbrain, consistent with prior [ 11 C]-(+)-PHNO research, and lower BP ND in CUD in the dorsal striatum, consistent with research using non-selective D 2 R/D 3 R radiotracers. Exploratory independent component analysis (ICA) identified three sources of BP ND (striatopallidal, pallidonigral, and mesoaccumbens sources) that represent systems of brain regions displaying coherent variation in receptor availability. The striatopallidal source was associated with estimates of regional D 2 R-related proportions of BP ND (calculated using independent reports of [ 11 C]-(+)-PHNO receptor binding fractions), was lower in intensity in CUD and negatively associated with years of cocaine use. By comparison, the pallidonigral source was associated with estimates of regional D 3 R distribution, was greater in intensity in CUD and positively associated with years of cocaine use. The current study extends previous D 2 R/D 3 R research in CUD, demonstrating both lower BP ND in the D 2 R-rich dorsal striatum and greater BP ND in the D 3 R-rich midbrain using a single radiotracer. In addition, exploratory ICA identified sources of [ 11 C]-(+)-PHNO BP ND that were correlated with regional estimates of D 2 R-related and D 3 R-related proportions of BP ND , were consistent with regional differences in CUD, and suggest receptor alterations in CUD may also be present in regions of mixed D 2 R/D 3 R concentration.
Introduction
Individuals with cocaine-use disorder (CUD) exhibit alterations in subcortical dopamine including alterations in receptor availability, blunted dopamine release and reduced dopamine transport mechanisms (Volkow et al., 1990 (Volkow et al., , 1996 (Volkow et al., , 1997 (Volkow et al., , 2014 Martinez et al., 2004 Martinez et al., , 2007 Narendran et al., 2012; Matuskey et al., 2014; Payer et al., 2014) . However, dopaminergic pharmacotherapies for stimulant-related addictions have displayed limited efficacy to date (see Pérez-Mañá et al., 2011; Minozzi et al., 2015) , thus a greater understanding of dopaminerelated alterations in CUD may improve targeted interventions for addictions. Alterations in dopamine type-2 and type-3 receptors (D 2 R/ D 3 R) are associated with CUD and other substance-use disorders (Volkow et al., 1990 (Volkow et al., , 1997 (Volkow et al., , 2001 (Volkow et al., , 2014 Martinez et al., 2004 Martinez et al., , 2005 Martinez et al., , 2007 Martinez et al., , 2012 Erritzoe et al., 2014; Fehr et al., 2008; Boileau et al., 2016) , suggesting related neurobiological mechanisms that may hold potential as targets in treating addictions. Specifically, D 2 R and D 3 R are implicated in the habitual and compulsive behaviors associated with the persistence of chronic drug use and relapse (Self, 2010) . Animal models demonstrate functional dissociation of D 2 R and D 3 R systems (Doherty et al., 2008; Banasikowski et al., 2010; Watson et al., 2012) , suggesting these dopamine receptor subtypes may provide distinct contributions to addictive processes.
Research using dopamine-antagonist radioligands with equal affinities for D 2 R and D 3 R (e.g., [ 11 C]raclopride ) indicate lower receptor availability in D 2 R-rich striatal regions of individuals with CUD (Volkow et al., 1990 (Volkow et al., , 1997 (Volkow et al., , 2014 Martinez et al., 2004 Martinez et al., , 2007 . By comparison, research using the D 3 R-preferring dopamine-agonist radioligand [ 11 C]-(+)-PHNO in CUD and stimulant addiction indicate increased receptor availability in the D 3 R-rich midbrain Payer et al., 2014; Boileau et al., 2012) . These concurrently upregulated and downregulated dopamine systems in CUD may undermine dopaminergic therapies for cocaine addiction. Adding to this complexity, D 2 R and D 3 R are both expressed in structures central to addiction (e.g., midbrain, ventral striatum, pallidum) (Gurevich and Joyce, 1999) , and assessing potential alterations of specific receptor subtypes in these regions is challenging.
Regional binding of [ 11 C]-(+)-PHNO reflects local concentrations of both D 2 R and D 3 R (Tziortzi et al., 2011; Searle et al., 2013) , allowing for simultaneous imaging of D 2 R/D 3 R not possible using other D 2 -like receptor radioligands. To date however, [ 11 C]-(+)-PHNO research of CUD has not replicated findings of lower receptor availability in the D 2 R-rich dorsal striatum, or detected alterations in mixed-D 2 R/D 3 R regions Payer et al., 2014) . However, these results of non-altered D 2 R-like availability in the striatum in CUD are consistent with research using alternative dopamine-agonist radioligands with equal affinities for D 2 R/D 3 R (e.g., [ 11 C]NPA) (Narendran et al., 2011) . The current study aimed to further examine D 2 R and D 3 R alterations in the midbrain, striatum and other subcortical structures (e.g., globus pallidus, ventral pallidum and hypothalamus) in CUD using [ 11 C]-(+)-PHNO positron emission tomography (PET) imaging. Investigation of regional [ 11 C]-(+)-PHNO BP ND was conducted on individuals with CUD and matched healthy comparison (HC) participants.
In addition, exploratory spatial independent component analysis (ICA) was performed on [ 11 C]-(+)-PHNO BP ND data to examine D 2 R and D 3 R using a source-based approach. ICA is a data-driven computational procedure that decomposes or 'un-mixes' a measured signal into its maximal spatially independent 'sources'. While [ 11 C]-(+)-PHNO exhibits an estimated 20-to 50-fold selectivity in vivo for D 3 R relative to D 2 R (Freedman et al., 1994; Gallezot et al., 2012; Rabiner et al., 2009) , local BP ND reflects a weighted sum of D 2 R/D 3 R concentrations. That is, [ 11 C]-(+)-PHNO BP ND primarily reflects D 3 R availability in D 3 -rich regions (e.g., substantia nigra), D 2 R availability in D 2 -rich regions (e.g., dorsal striatum), and an aggregate of D 2 R and D 3 R availability in mixed D 2 R/D 3 R regions (e.g. ventral striatum) (Tziortzi et al., 2011; Searle et al., 2013 Searle et al., , 2010 Graff-Guerrero et al., 2010) . This unique mixed-signal nature of [ 11 C]-(+)-PHNO strongly motivates the utility of source-based analyses like ICA to un-mix the D 2 R and D 3 R components of BP ND and examine distinct sources of receptor availability.
We hypothesized that CUD-related reductions in D 2 R availability in the dorsal striatum would be detectable using [ 11 C]-(+)-PHNO in a large sample, and that CUD-related increases in D 3 R availability in the midbrain would be confirmed. We also hypothesized that the exploratory ICA would identify sources of [ 11 C]-(+)-PHNO BP ND consistent with estimates of regional proportions of D 2 R-related and D 3 R-related BP ND , with mixed-D 2 R/D 3 R regions incorporated into multiple sources. Consistent with research demonstrating regional differences in D 2 R and D 3 R in CUD, we hypothesized that individuals with CUD would exhibit increased intensity of sources that include D 3 -rich regions and reduced intensity of sources that include D 2 -rich regions. Finally, we examined relationships between regional BP ND and source intensities with duration of cocaine use.
Methods and materials

Participants
Participants were 26 non-treatment seeking individuals with CUD and 26 age-and gender-matched HC participants, most of whom (22 CUD and 21 HC) were included in previous reports (Matuskey et al., , 2015 (Table 1) . Physical exams with medical history, routine laboratory studies, pregnancy tests and electrocardiograms (ECGs) were performed to assess medical health eligibility criteria. Urine toxicology screening for a range of drugs (including cocaine, amphetamines, marijuana, opiates, benzodiazepines, barbiturates) were performed to confirm cocaine-use status in CUD participants and the absence of other recent drug use in both CUD and HC participants. Participants were assessed for DSM-IV diagnoses using clinical interviews (SCID (First et al., 2002) ; MINI (Sheehan et al., 1998) ). Participants meeting criteria for cocaine dependence (i.e., presenting with 3 or more criteria) were included in the CUD sample. Exclusion criteria included the presence or history of a general medical illness or psychotic disorder, pregnancy or breast feeding, or any condition that would interfere with the ability to participate in PET or MRI protocols (e.g., claustrophobia, metallic implants). All study procedures were approved by the Yale Human Investigation, Yale University Radiation Safety, Yale-New Haven Hospital Radioactive Drug Research, and Yale MRI Safety Committees, and participants provided written informed consent.
Radiochemistry and image acquisition
[ 11 C]-(+)-PHNO was prepared as previously described Wilson et al., 2005) . Radioactive dose, specific activity and injected mass for CUD and HC groups are listed in Table 1 . PET imaging was performed on a Siemens high-resolution research tomograph (HRRT; Siemens/CTI, Knoxville, TN, USA). A transmission scan was obtained before the emission scan. PET scans (slices=207, slice separation=1.2 mm, reconstructed image resolution ∼3 mm) were acquired for 120 min at rest. Head motion was measured using an optical detector (Vicra, NDI Systems, Waterloo, Ontario, Canada). MR images were collected on a Siemens 3T Trio system (Siemens Medical Solutions, Malvern, PA) using a magnetization prepared rapid acquisition gradient echo (MPRAGE) sequence (repeat time (TR)/echo time (TE)=2530/3.34, flip angle=7°, in-plane resolution=0.98x0.98 mm, matrix=256x256, slice thickness=1 mm, slices=176). 
Image processing
Dynamic PET data (frame timing: 6x30 s; 3x60 s; 2×120s; 22×300 s) were reconstructed with corrections (attenuation, normalization, scatter, randoms, deadtime and motion) using the MOLAR algorithm (Carson et al., 2003) . Parametric images of [ 11 C]-(+)-PHNO BP ND were computed using a simplified reference tissue model (SRTM2 (Wu and Carson, 2002) ) with the cerebellum as reference (Gallezot et al., 2011) . Registration of individual images into MNI152 space (Mazziotta et al., 2001) was performed using SPM12 (Wellcome Trust Centre for Neuroimaging, London, UK). A summed [ 11 C]-(+)-PHNO uptake (0-10 min post-injection) image was created from the motion-corrected PET data and rigid-body registered to the subject's MR image. Nonlinear registration of the MR image to MNI152 space was determined using optimized unified segmentation (Ashburner and Friston, 2005) . The combined rigid-body and nonlinear registrations were applied to the parametric BP ND , and smoothed with a 4mm FWHM Gaussian kernel.
Analyses of regional [ 11 C]-(+)-PHNO BP ND
Seven regions of interest (ROIs) were examined: dorsal caudate (DCA), dorsal putamen (DPU), globus pallidus (GP), hypothalamus (HY), substantia nigra (SN), ventral pallidum (VP), and ventral striatum (VS). ROIs were defined using previously described guidelines (Tziortzi et al., 2011; Mawlawi et al., 2001) . DCA, DPU and VS ROIs were obtained from FSL (Oxford Centre for Functional MRI of the Brain, Oxford, UK (Tziortzi et al., 2011) ). GP, HY, and VP ROIs were manually drawn on the ICBM-MNI52 template (Montreal Neurological Institute, Montreal, Canada). The SN ROI was manually defined on a group-average parametric [ 11 C]-(+)-PHNO BP ND image from an independent sample . Regional [ 11 C]-(+)-PHNO BP ND was determined from the individual smoothed parametric BP ND images in standard space. ROI volumes were calculated by inverse transformation of template regions into individual native space. A confirmatory whole-brain, between-group analysis was performed on BP ND images using a two-sample t-test in SPM12 with a relative threshold mask (0.8; displayed in Fig. 1 ). Due to the relatively low BP ND signal (less than 0.5) in the thalamic and amygdala regions included in previous reports, substantial portions of these structures did not survive threshold masking and thus were excluded from ROI analyses. Group differences were explored at an uncorrected significance level of p < 0.005, and cluster extent (k) > 20 contiguous voxels.
Independent component analysis (ICA)
Exploratory ICA was performed on parametric images of [ 11 C]-(+)-PHNO BP ND using the source-based morphometry (SBM (Xu et al., 2009 )) module of the Group ICA of fMRI Toolbox (GIFT v2.0e; http:// mialab.mrn.org/software/gift). Using higher order statistics, ICA identifies maximally independent vectors that comprise an unknown linear mixture (A) of mostly non-Gaussian sources (s) that generate a random variable (x). Given x As = , ICA solves for y Wx = , or the estimated un-mixing matrix (W) of approximated source maps (y). Parametric images of all 52 participants were entered into the ICA to allow direct comparison of source loadings. The analysis was constrained to data within the relative threshold mask determined in the GLM analysis (described above), and with no prior information as to group membership. A modified minimum-description-length (MDL) criterion (Li et al., 2007) estimated the dimensionality of the dataset to consist of three sources which were extracted from the aggregate dataset using a neural-network algorithm designed to minimize mutual information of source outputs (InfoMax (Bell and Sejnowski, 1995) , is the average subject intensity for source M, and:
where x ∼ is the approximate reconstruction of the original data x, 
. For display and anatomical assignment purposes, the scaled source maps were thresholded at B P ∼ M ≥0.5 (with no cluster-extent threshold) based on the relevant range of [ 11 C]-(+)-PHNO BP ND of 1.5-4.
To examine source compositions relative to regional estimates of D 2 R/D 3 R availability, intensity-scaled source maps were generated for all subjects, and regional B P ∼ M values were extracted from the seven ROIs and compared the D 2 R-related and D 3 R-related proportions of BP ND calculated using reported regional fractions of [ 11 C]-(+)-PHNO BP ND (Tziortzi et al., 2011; Searle et al., 2013) . That is, regional BP ND values obtained in the ROI-based analysis (see Section 2.4. and Fig. 1 ) were multiplied by average D 2 R-and D 3 R-related fractions reported in (Gurevich and Joyce, 1999; Tziortzi et al., 2011) ( Supplementary  Table 1 ) to obtain regional estimates of local D 2 R/D 3 R BP ND (i.e.,
3 ). Average regional B P ∼ M for each source were then examined in relation to the calculated estimates ofBP ND D2 and BP ND D3 using Pearson correlations to assess potential association with D 2 R-related and D 3 R-related BP ND proportions.
Statistical procedures
Group differences in ROI BP ND values and ICA source intensities were assessed with two separate multivariate analyses of variance (i.e., group x ROI and group x source) and post-hoc univariate analyses. Due to non-tracer conditions of [ 11 C]-(+)-PHNO for D 3 R at the administered dose (Searle et al., 2013) , multivariate analyses including the estimated free concentration of [ 11 C]-(+)-PHNO (based on the average mass concentration in the cerebellum from 90-120 min, multiplied by the specific activity) as a covariate were performed and revealed no significant mass dose effect on results (p's > 0.4). Given reported associations between [ 11 C]-(+)-PHNO BP ND and age and body-mass Matuskey et al., 2016; Nakajima et al., 2015) , all between-group multivariate and univariate analyses were repeated adjusting for age and body-mass. Additional analyses were performed to examine potential influences of alcohol use across all participants (Erritzoe et al., 2014; Martinez et al., 2005) and cigarette smoking (Fehr et al., 2008) within CUD participants. Exploratory correlational analyses were performed to examine relationships between regional and source-based binding measures with years of cocaine use.
Results
Participant characteristics and radioactivity information are provided in Table 1 . There were no group differences in body-mass or radiotracer injection parameters. CUD participants were more likely to be daily tobacco smokers (χ 2 =32.4, p < 0.001) and did not differ from HCs in weekly alcohol consumption. ROI volumes (in subject/native space) did not differ between groups (p's > 0.1).
Regional analyses of [ 11 C]-(+)-PHNO BP ND
Results of ROI and whole-brain analyses are displayed in Fig. 1 . There was a main effect of group across ROIs (F 7,44 =3.87, p=0.002), with CUD relative to HC displaying greater BP ND in the SN (t 50 =2.91, p=0.005) and lower BP ND in the DPU (t 50 =2.14, p=0.037), while a group difference in the DCA did not reach significance (t 50 =1.79, p=0.080) ( Fig. 1a ). Whole-brain analysis confirmed CUD relative to HC participants exhibited greater BP ND in the midbrain and lower BP ND in the dorsal striatum (Fig. 1b) . Consistent with previous reports Nakajima et al., 2015; Gaiser et al., 2015) , there was a significant association between age and BP ND (F 7,42 =3.25, p=0.008), and a marginal association between body-mass and BP ND (F 7,42 =2.23, p=0.051). Adjusting for influences of age and body-mass, group differences in the SN remained significant (F 1,48 =11.29, p=0.002) while differences in the DPU did not reach significance (F 1,48 =3.72, p=0.060). There was no main effect of alcohol use on BP ND (F 7,44 =0.87, p=0.54), and group differences survived adjusting for the number of cigarettes smoked daily (F 7,43 =3.89, p=0.002). Within CUD participants, there was no association between BP ND and daily cigarettes smoked (F 7,18 =0.55, p=0.79) or years of cocaine use (F 7,18 =1.07, p=0.42).
ICA of [ 11 C]-(+)-PHNO BP ND
The exploratory ICA identified three sources of [ 11 C]-(+)-PHNO binding that represent systems of brain regions displaying coherent variation in BP ND through the sample (Fig. 2; Table 2 ). Source 1 represented a 'striatopallidal source', with largest contributions in the DPU, DCA, GP, VP and VS. Source 2 represented a 'pallidonigral source' comprised of the SN, GP, VP and HY. Source 3 represented a ventral 'mesoaccumbens source' encompassing HY, VP, VS and anterior regions of the midbrain extending into the SN. Although extracted solely from the data, the identified sources were spatially consistent with the distribution of D 2 R-related and D 3 R-related availability across regions of interest (Fig. 3) . Specifically, regional B P ∼ M values of the striatopallidal source were associated with estimated D 2 R-related BP ND proportions (r=0.89, p=0.008), and regional B P ∼ M of the pallidonigral source were associated with estimated D 3 R-related BP ND proportions (r=0.89, p=0.007). The mesoaccumbens source was not associated with either D 2 R-related or D 3 R-related binding proportions (p's > 0.1).
ICA subject intensities for the three sources did not correlate with each other (p's > 0.2). There were no associations between source intensities and age (F 3,46 =1.53, p=0.22) or body-mass (F 3,46 =1.80, p=0.16). There was no main effect of alcohol use on source intensities (F 3,46 =1.48, p=0.23). 
[ 11 C]-(+)-PHNO BP ND sources and CUD
There was a main effect of group on ICA-intensity across the three identified sources (F 3,48 =4.28, p=0.009). CUD relative to HC participants displayed lower intensities of the striatopallidal source (t 50 =2.58, p=0.013; Fig. 3a ) and greater intensity of the pallidonigral source (t 50 =2.03, p=0.047; Fig. 3b ). Group differences in the mesoaccumbens source did not reach significance (t 50 =1.63, p=0.109). Different from the regional analysis above, the intensity of the striatopallidal source was negatively associated with years of cocaine use (r=0.39, p=0.048; Fig. 3a ) and pallidonigral source intensity was positively correlated with years of cocaine use (r=0.40, p=0.042; Fig. 3b ). Group differences survived adjusting for the number of cigarettes smoked daily (F 3,47 =4.28, p=0.009), and within CUD participants there was no association between source intensities and the number of cigarettes smoked daily (F 3,22 =0.75, p=0.53).
Discussion
The current study extends prior research of D 2 R/D 3 R availability in CUD using [ 11 C]-(+)-PHNO. Regional analyses revealed CUD-related dorsal striatal reductions in D 2 R-related BP ND , consistent with D 2 R/D 3 Rantagonist radioligand research (Volkow et al., 1990 (Volkow et al., , 1997 (Volkow et al., , 2014 Martinez et al., 2004 Martinez et al., , 2007 but not previously detected with the D 3 Rpreferring [ 11 C]-(+)-PHNO, and confirmed greater availability in the SN in CUD Payer et al., 2014) . Exploratory ICA identified three sources of [ 11 C]-(+)-PHNO BP ND that were correlated with regional proportions of D 2 R-related and D 3 R-related BP ND and spatially consistent with known subcortical dopamine circuitry. Individuals with CUD relative to HC exhibited reduced intensity of a D 2 R-related striatopallidal source and greater intensity of a D 3 Rrelated pallidonigral source that were both associated with years of cocaine use, an association not found when analyzing regions individually. Notably, the ICA-identified sources suggest CUD-related alterations may be present in regions of mixed D 2 R/D 3 R concentration (e.g., ventral striatum, globus pallidus) not previously observed using traditional analyses of D 2 R/D 3 R radioligands. The current findings underscore the advantage of [ 11 C]-(+)-PHNO in simultaneous investi- Regional composition of ICA-identified sources at the threshold of ICA-estimated BP ND contribution (B P ∼ M ) ≥0.5. Cluster information includes spatial extent (k, in voxels), peak location (x, y, z) in MNI152 space and peak B P ∼ M . Abbreviations: DCA, dorsal caudate; DPU, dorsal putamen; GP, globus pallidus; HY, hypothalamus; SN, substantia nigra; VP, ventral pallidum; VS, ventral striatum; R/L, right/left hemisphere. Fig. 3 . Source associations with estimated regional D 2 R-related and D 3 R-related BP ND proportions, group intensity differences and correlation with years of cocaine use for the (a) striatopallidal and (b) pallidonigral sources. Regional estimates of D 2 R-related and D 3 R-related BP ND were calculated using reported fractions of [ 11 C]-(+)-PHNO BP ND (24, 25) (see Section 2.5). Subject ICA-loadings refer to the mixing parameter representing source intensity, or how strongly each source contributed to the aggregate BP ND signal . Error bars indicate SD. *p < 0.05. gation of both D 2 R and D 3 R alterations in addictions, especially when combined with ICA in exploring sources of dopamine receptor availability. The patterns of concurrently increased and decreased receptor availability, particularly within structures (e.g., the ventral striatum), lend insight into the clinical challenges of dopaminergic pharmacotherapy for CUD.
4.1. Regional [ 11 C]-(+)-PHNO BP ND in CUD Alterations in D 2 -like receptor systems in CUD have been reported using multiple radioligands, and the current ROI and whole-brain observations of greater midbrain and reduced dorsal striatal BP ND are consistent with previous research (Volkow et al., 1990 (Volkow et al., , 1997 (Volkow et al., , 2014 Martinez et al., 2004 Martinez et al., , 2007 Martinez et al., , 2014 Payer et al., 2014) . Reduced D 2 Rrelated BP ND in the striatum and greater D 3 R-related BP ND in the SN and have been linked to increased impulsivity in cocaine/stimulant addictions (Payer et al., 2014; Lee et al., 2009) . Lower striatal D 2 R BP ND has been associated with poor behavioral therapy outcomes in CUD . The relationship between reduced striatal BP ND and years of cocaine use in the current study is consistent with preclinical evidence of the effects of cocaine exposure on D 2 R availability (Nader et al., 2006) . Similarly, increases in D 3 R systems follow cocaine exposure in animal models (Conrad et al., 2010; Neisewander et al., 2004) , though the previous finding of a relationship between D 3 R-related SN BP ND and years of cocaine use was not replicated in the current regional analysis. Dissociating potential dopaminergic vulnerabilities to addictive disorders and dopaminergic consequences of substance use remains an important area of addictions research (Volkow et al., 2015) .
Sources of [ 11 C]-(+)-PHNO BP ND
ICA identified three sources of [ 11 C]-(+)-PHNO BP ND that were correlated with estimated regional proportions of D 2 R-related and D 3 R-related BP ND and spatially consistent with dopamine circuitry. The striatopallidal source was identified in nodes of the 'indirect' dopamine pathway linking the striatum (DPU, DCA and VS) to the SN through connections with the pallidum (GP and VP). The indirect pathway is comprised of D 2 R-expressing GABAergic medium spiny neurons interconnecting the striatum and pallidum. Consistent with this indirect pathway anatomy, the intensity of the identified striatopallidal source was strongly associated with estimated regional D 2 R components of [ 11 C]-(+)-PHNO BP ND (Tziortzi et al., 2011; Searle et al., 2013) . Preclinical models indicate striatopallidal D 2 R mechanisms may counterbalance reward-related responsivity, with impaired functioning associated with a greater sensitivity to drug-related rewards (Ferguson et al., 2011) . Evidence also suggests a role of indirectpathway striatal D 2 R with behavioral inflexibility relative to aversive conditions (Hikida et al., 2013; Kravitz et al., 2012) and compulsive cocaine-seeking (Bock et al., 2013) .
The pallidonigral source identified by ICA was composed of regions highly correlated with estimates of regional proportions of D 3 R [ 11 C]-(+)-PHNO BP ND (Tziortzi et al., 2011; Searle et al., 2013) . The pallidonigral source is spatially consistent with dopamine circuitry between the pallidal structures and the midbrain. While less is understood regarding specific functionality of D 3 R systems, integration of GP, VP and SN regions suggest a role of this system in drug-related reinforcement processing and motivational/appetitive states (Kalivas and Volkow, 2005) . Incentive salience models of addiction identify 'wanting' as a motivation state, dissociable from the hedonic state of 'liking', as a process that becomes sensitized over the course of an addiction (Robinson et al., 2015) , and is associated with greater D 3 R availability in the SN in polysubstance and methamphetamine users (Boileau et al., 2016 (Boileau et al., , 2012 .
The mesoaccumbens source was identified in SN, VS and VP regions. While the SN and VP are D 3 R-rich regions, there was no relationship between regional source intensities and estimated D 3 Rrelated (or D3R-related) proportions of [ 11 C]-(+)-PHNO BP ND across ROIs. Decreased D 2 R/D 3 R availability in the SN and VS is associated with increased sensitivity to reinforcing effects of stimulants mediated through increased striatal dopamine release (Buckholtz et al., 2010) . Neuroadaptive increases in SN and VS D 3 R associated with cocaine exposure (Neisewander et al., 2004; Staley and Mash, 1996) may act to downregulate the stimulant-induced release of dopamine in the striatum in individuals with CUD (Martinez et al., 2007; Volkow et al., 2014) . While a functional role of D 2 R/D 3 R in VS and midbrain circuitry appears critical in balancing dopamine transmission in CUD, mesoaccumbens source intensities were not altered in CUD (or associated with years of cocaine use), and additional research and/or validation of the reliability of this source is warranted.
Clinical implications of D2-like receptor sources in addictive disorders
CUD-related differences in source intensities were consistent with regional analyses, broadly identifying lower D 2 R-related and greater D 3 R-related source intensities. ICA-identified sources extend individual regional observations, detecting CUD-related differences in regions characterized by mixed-D 2 R/D 3 R concentrations. Patterns of source-intensity difference suggest concurrent upregulation and downregulation of receptor availability in the VS and pallidal regions. In the current study, alterations in striatopallidal and pallidonigral sources, proposed to reflect complementary mechanisms of the indirect dopamine pathway, were associated with years of cocaine use. The intensities of these two sources were significantly related to CUD chronicity, suggesting receptor alterations may represent reciprocal compensatory adaptations through the course of addiction.
Despite extensive efforts to identify effective pharmacotherapies for CUD, there is currently no FDA-approved medication with an indication for CUD. Although it has been proposed that dopamine-agonist therapies may aid in the maintenance of cocaine abstinence (Negus and Henningfield, 2014) , preclinical evidence of the influences of D 2 R and D 3 R agonists and antagonists on cocaine-related behaviors is mixed (Caine et al., 2012; Cheung et al., 2013; Mello et al., 2013; Caine et al., 2002) . The current findings illustrate the underlying complexity of targeting receptor subtypes that may integrate into multiple functional systems and influence drug-related behavior differently depending on the region of action (David et al., 2002) . Adding to the challenge of dopaminergic pharmacotherapies are the neuroplastic adaptations associated with cocaine exposure and chronic use, suggesting dopaminergic interventions may be aimed at 'moving targets', resulting in heterogeneous response profiles across individuals at different stages of addiction.
Strengths and limitations
The current study investigated the largest sample of CUD participants completing [ 11 C]-(+)-PHNO PET to date (N=26 relative to previous samples that included 10 to 16 individuals Payer et al., 2014; Matuskey et al., 2015) ), and demonstrates [ 11 C]-(+)-PHNO sensitivity to reductions in dorsal striatal D 2 R availability frequently reported in CUD using equal-affinity D 2 R/D 3 R antagonist radioligands. The current sample was largely comprised of previously reported subjects. ROI results of CUD-related BP ND alterations in the DPU survived post-hoc analysis co-varying for cohort (p=0.03), suggesting greater statistical power (rather than potential differences in individual variability across independent cohorts) contributed to the significant detection of D 2 R-related differences in individuals with CUD. This study also represents the first application of ICA to explore sources of covarying D 2 R/D 3 R availability and examine alterations associated with CUD.
The data-driven ICA extraction was blind to the spatial distribu-tions of D 2 R/D 3 R concentrations and blind to subject group assignments. The current mixed-sample design, while allowing direct comparison of source intensities in CUD relative to HC, identified three sources of [ 11 C]-(+)-PHNO BP ND and alternative strategies of component extraction (e.g., higher-dimension ICA) may identify alternative sources (Abou-Elseoud et al., 2010) . Alternative computational strategies (e.g., principal component analysis; PCA) have also been used to investigate PET data using ROI-based and voxel-wise approaches (Zald et al., 2010; Zuendorf et al., 2003) , and may identify different factor structures in [ 11 C]-(+)-PHNO data. Proposed associations with D 2 R-related and D 3 R-related availability in identified sources were based on calculated estimates using fractions of D 3 R-related [ 11 C]-(+)-PHNO BP ND derived in healthy controls using antagonists that are not 100% selective for D 3 R receptors (Tziortzi et al., 2011; Searle et al., 2013) . Thus, imprecise estimates, and potentially altered regional D 2 R/D 3 R-related fractions in individuals with CUD, limit conclusive determination of source signals relative to receptor subtypes. Research using ICA in conjunction with specific D 2 R and D 3 R blocking agents would be needed to validate these exploratory source compositions. Similarly, interpretations of potential functional involvement of identified sources was based on spatial patterns of regional integration relative to the extant and evolving literature, and direct examination of source relationships with measures of impulsivity, compulsivity, and substance use-related domains (e.g., self-administration, craving and cue-reactivity) may reveal alternative associations. Potential influences of co-occurring nicotine dependence in CUD participants on D 2 R/D 3 R availability warrants consideration given group differences in regular tobacco smoking (Fehr et al., 2008) . Though daily smoking amounts were not associated with PET results within CUD participants, future studies including a nicotine-dependent comparison sample would allow examination of cocaine-specific alterations in D 2 R/D 3 R receptor systems. Additional research is needed to replicate current observations and explore these dopamine systems in other addictive disorders.
Conclusions
The current study extends previous research of regional D 2 R/D 3 R availability in CUD measured with [ 11 C]-(+)-PHNO, detecting lower BP ND the dorsal striatum and replicating greater BP ND in the midbrain. Source-based analysis using ICA identified three distinct sources of BP ND , indicating lower intensity of a striatopallidal source and greater intensity of a pallidonigral source in CUD. These source-based patterns of BP ND suggest cocaine-related alterations in D 2 R and D 3 R may not be limited to the dorsal striatum and midbrain respectively, but may extend into the pallidum and ventral striatum. Furthermore, the alterations in striatopallidal and pallidonigral sources were associated with duration of cocaine use, and may indicate reciprocal and compensatory mechanisms of dopaminergic function in addiction. Additional investigation into concurrent alterations in D 2 -like dopamine receptor systems (e.g., prior to drug exposure, during initial use and withdrawal, and following extended abstinence) should provide important insight into treatment development efforts for CUD.
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